Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double-blind trial of onabotulinumtoxinA injection into corpora cavernosa for erectile dysfunction refractory to PDE5 inhibitors
2024-514518-10-00Phase 2Authorised
- Sponsor
- Clínica Universidad de Navarra
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in erectile dysfunction (ED) comparing OnabotulinumtoxinA arm with Placebo arm (2 arms). Primary endpoint: Subjective perception of rigidity. Planned start Sep 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on 2024-514518-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514518-10-00.